Videos

The Center for Biosimilars® spoke with George Williams, MD, clinical spokesperson for the American Academy of Ophthalmology (AAO), about the FDA’s recent approval of Byooviz (ranibizumab), the first biosimilar specifically approved for treatment of eye diseases.

The HHS plan ordered up by President Biden for combatting high drug prices is a hodgepodge of ideas that have long circulated in Washington, DC, but can any of them be made to stick? An intellectual property and FDA policy expert, Chad Landmon, JD, shares his perspective.

Here are the top 5 biosimilar articles for the week of September 13, 2021.

Here are the top 5 biosimilar articles for the week of September 6, 2021.

Gary Lyman, MD, MPH, an oncologist and hematologist, explains that biosimilar substitution in the absence of interchangeability designations is widespread and not without clinical merit.

Here are the top 5 biosimilar articles for the week of August 30, 2021.

Catherine Swick, MBA, senior vice president of Provider Strategy and Marketing at McKesson, discusses efforts to get oncology biosimilars into play at US Oncology Network.

Here are the top 5 biosimilar articles for the week of August 23, 2021.

Gary Lyman, MD, MPH, an oncologist and hematologist, discusses how biosimilar placement on formularies affects physicians' willingness to prescribe these agents.

Here are the top 5 biosimilar articles for the week of August 16, 2021.

Chad Pettit, MBA, executive director of Marketing and the Global Biosimilars commercial lead for Amgen, discussed the company’s 2021 Biosimilar Trends Report and his projections for the future of the biosimilars market.

Here are the top 5 biosimilar articles for the week of August 9, 2021.

Health care systems need to consistently reevaluate whether the biosimilars they utilize are the most cost-effective, Neal Dave, PharmD, the executive director of pharmacy at Texas Oncology, explains.

Here are the top 5 biosimilar articles for the week of August 2, 2021.

Here are the top 5 biosimilar articles for the week of July 26, 2021.

Here are the top 5 biosimilar articles for the week of July 19, 2021.

Here are the top 5 biosimilar articles for the week of July 12, 2021.

Chad Landmon, JD, chair of Intellectual Property and FDA Practice at Axinn, Veltrop & Harkrider, provides a legal perspective on the implications of President Biden’s effort to improve the competitiveness of drug markets.

Here are the top 5 biosimilar articles for the week of July 5, 2021.

Here are the top 5 biosimilar articles for the week of June 28, 2021.

Here are the top 5 biosimilar articles for the week of June 21, 2021.

Tahir Amin, Dip LP, co-executive director of I-MAK, discusses some hot-button issues regarding the US patent system, including AbbVie’s alleged abuse of it, and his hopes for improvement.

Here are the top 5 biosimilar articles for the week of June 14, 2021.

Product differentiation, global partners, and a large suite of biosimilars in development are ways that Reykjavik, Iceland-based Alvotech expects to stay ahead of the competition.

In part 2 of this panel discussion, 3 experts on India’s biologics industry discuss whether biosimilars can be produced affordably in the country and ways of improving the industry’s image.

Here are the top 5 biosimilar articles for the week of June 7, 2021.

In part 1 of this panel discussion, 3 experts on India’s biologics industry explain what’s missing from current biosimilar regulation and what the country needs to do for its products to compete internationally.

Here are the top 5 biosimilar articles for the week of May 31, 2021.

In part 2 of this interview, Cate Lockhart, PharmD, PhD, executive director of the Biologics and Biosimilar Collective Intelligence Consortium, discusses the potential for interchangeable insulin biosimilars and the challenges of obtaining reliable and optimized real world data.

Here are the top 5 biosimilar articles for the week of May 24, 2021.